| Drug Name |
Doripenem |
| Drug ID |
BADD_D00710 |
| Description |
Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications. |
| Indications and Usage |
Doripenem is indicated in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, caused by designated susceptible bacteria.
|
| Marketing Status |
approved; investigational |
| ATC Code |
J01DH04 |
| DrugBank ID |
DB06211
|
| KEGG ID |
D03895
|
| MeSH ID |
D000077726
|
| PubChem ID |
73303
|
| TTD Drug ID |
D03QWT
|
| NDC Product Code |
Not Available |
| UNII |
BHV525JOBH
|
| Synonyms |
Doripenem | 2-(5-sulfamoylaminomethylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylic acid | S 4661 | S-4661 | S4661 |
